Prelude Therapeutics
Clinical trials sponsored by Prelude Therapeutics, explained in plain language.
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or combined with other drugs (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to find a safe dose and check for side effects. Re…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new drug called PRT3789, alone or with chemotherapy (docetaxel), in 135 people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation). The main goals were to check safety, find the best dose, and see if the drug shrinks t…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:47 UTC